GO
Loading...

Roche Holding AG

More

  • UK's Cameron calls for global action on superbug threat Wednesday, 2 Jul 2014 | 4:06 AM ET

    *Economist Jim O'Neill to head new antibiotics panel. LONDON, July 2- Prime Minister David Cameron called on Wednesday for global action to tackle the threat of drug-resistant superbugs and said Britain planned to take a leading role in finding ways to spur the development of new antibiotics.

  • *Roche adds to breast cancer drug offering with Seragon. Roche is looking to bolster its offering of breast cancer drugs with the purchase. Since walking away from a $6.8 billion deal to buy U.S gene sequencing company Illumina in 2012 Roche has eschewed multi-billion deals and instead snapped up a couple of smaller diagnostic companies so far this year.

  • June 30- Allergan Inc said on Monday that the U.S. Food and Drug Administration would not approve its acute migraine aerosol treatment until certain concerns are addressed, but the agency approved a new use for its implantable eye drug, Ozurdex.

  • WASHINGTON/ MUMBAI, June 27- India's Ranbaxy Laboratories Ltd has received approval from the U.S. Food and Drug Administration to launch a cheaper copy of Novartis AG's blood pressure pill Diovan, bolstering its outlook after a raft of regulatory bans for poor production quality at its India facilities dented investor sentiment.

  • June 24- A late-stage trial testing Bristol-Myers Squibb Co's cancer immunotherapy nivolumab in advanced melanoma patients was halted early after it was determined that the drug was likely to prolong survival, the company said on Tuesday.

  • UPDATE 1-Ohr Pharma eye drug falls short in trial Tuesday, 24 Jun 2014 | 8:16 AM ET

    June 24- Ohr Pharmaceutical Inc said its experimental eye drop showed no significant benefit over a placebo in reducing the number of injections of another drug directly into the eye, but improved patients' visual clarity.

  • Will ghoulish investments pay off? Monday, 16 Jun 2014 | 6:57 PM ET
    Elderly women wait for lunch to be served at a day care facility on Gogo Island in Matsuyama, Ehime Prefecture, Japan

    As the global population ages, some see investment opportunities in somewhat ghoulish bets the rates of cancer and other illnesses will rise.

  • June 16- A drug approved to prevent rejection of transplanted kidneys significantly reduced relapses of multiple sclerosis in a late stage-trial sponsored by Biogen Idec and AbbVie Inc, but serious infections and potential liver toxicity continued to cloud the drug's future.

  • SHANGHAI, June 13- China's crackdown on corruption in the pharmaceutical sector has frightened foreign executives so much that some fear they could be jailed and have asked their lawyers if they should leave the country for six months.

  • A takeover bid that caused much consternation didn't even go through after AstraZeneca PLC said "no thanks" to Pfizer Inc. in April. The episode caused Eric Sappenfield, co-manager of the John Hancock Global Shareholder Yield Fund, to turn cautious on Pfizer, although he still owns some.

  • CNBC's Meg Tirrell and Daniel O'Day, Roche Holdings COO, discuss the latest developments in immunotherapy and treating bladder cancer.

  • What new GSK cancer deal shows about pharma market Monday, 2 Jun 2014 | 3:33 AM ET

    The announcement that GSK is planning to spend $350 million plus to get a slice of a U.K. biotech's cancer drugs has raised eyebrows.

  • BEIJING, May 29- Johnson& Johnson, Bausch& Lomb Inc and other major producers have been fined more than 19 million yuan for fixing prices in China's eye glass and contact lens market, China's top economic regulator said on Thursday. Swiss drugmaker Roche Holding AG had also been visited by a unit of China's anti-trust regulator.

  • Chinese city targets pharma firms in graft crackdown Tuesday, 27 May 2014 | 9:08 AM ET

    SHANGHAI, May 27- China's eastern city of Hangzhou is cracking down on graft in the healthcare sector, according to an internal memo from the local government, putting more pressure on global drugmakers operating in the country.

  • How AstraZeneca escaped Pfizer clutches...this time Tuesday, 27 May 2014 | 8:20 AM ET

    Could things have turned out differently? Yes, according to one source in the AstraZeneca camp who pointed to a flaw in Pfizer's strategy.

  • *China anti-trust watchdog visits Roche office. *China cracking down on wider pharma sector. SHANGHAI/ ZURICH, May 22- Swiss drugmaker Roche Holding AG said it had been visited by a unit of China's anti-trust regulator- a move that comes amid a widening crackdown on corruption and high prices in the country's pharmaceutical sector.

  • Drugmaker Roche says visited by authorities in China Thursday, 22 May 2014 | 3:04 AM ET

    SHANGHAI/ ZURICH, May 22- Swiss drugmaker Roche Holding AG said on Thursday it had been visited by a unit of China's anti-trust regulator, amid increasing scrutiny over business practices in the pharmaceutical sector in the country.

  • SHANGHAI, May 18- Chinese corruption charges against executives of British drugmaker GlaxoSmithKline Plc could be just the start of the pharmaceutical industry's problems in its biggest emerging drugs market, according to industry sources in China.

  • May 14- When the world's leading cancer doctors meet in Chicago next month, new treatments from Merck& Co, Bristol-Myers Squibb Co and Roche Holding AG that help the immune system fight disease are expected to capture much of the spotlight.

  • May 14- When the world's leading cancer doctors meet in Chicago next month, new treatments from Merck& Co, Bristol-Myers Squibb Co and Roche Holding AG that help the immune system fight disease are expected to capture much of the spotlight.